drugset
drugset / Trial / NCT03410654

Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

NCT03410654 ↗

Phase 0 Completed 28 enrolled Yale University Veloxis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if cognitive function improves in patients converted from tacrolimus immediate release (TAC IR) to Envarsus XR® (tacrolimus extended release) using an objective measure of cognition.

Timeline

Start
2018-10-24
Primary completion
2024-01-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — —

Indications

No indication recorded.